Institutional Investor Sentiment About PROTEON THERAPEUTICS INC (NASDAQ:PRTO) Increased

December 8, 2017 - By Nellie Frank

 Institutional Investor Sentiment About PROTEON THERAPEUTICS INC (NASDAQ:PRTO)  Increased


PROTEON THERAPEUTICS INC (NASDAQ:PRTO) institutional sentiment decreased to 0.54 in 2017 Q2. Its down -4.13, from 4.67 in 2017Q1. The ratio fall, as 7 institutional investors started new or increased positions, while 13 reduced and sold their positions in PROTEON THERAPEUTICS INC. The institutional investors in our partner’s database now own: 7.14 million shares, down from 12.10 million shares in 2017Q1. Also, the number of institutional investors holding PROTEON THERAPEUTICS INC in their top 10 positions was flat from 3 to 3 for the same number . Sold All: 3 Reduced: 10 Increased: 2 New Position: 5.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $32.60 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

It closed at $1.85 lastly. It is down 80.63% since December 8, 2016 and is downtrending. It has underperformed by 97.33% the S&P500.

Analysts await Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report earnings on March, 15. They expect $-0.41 earnings per share, up 2.38 % or $0.01 from last year’s $-0.42 per share. After $-1.08 actual earnings per share reported by Proteon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -62.04 % EPS growth.

Deer Vii & Co. Ltd. holds 15.66% of its portfolio in Proteon Therapeutics, Inc. for 315,101 shares. Abingworth Llp owns 2.02 million shares or 2.41% of their US portfolio. Moreover, Mpm Asset Management Llc has 0.65% invested in the company for 983,381 shares. The Massachusetts-based Ra Capital Management Llc has invested 0.23% in the stock. Deerfield Management Co, a New York-based fund reported 1.22 million shares.#img1#

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Ratings Coverage

Ratings analysis reveals 13% of Proteon Therapeutics’s analysts are positive. Out of 8 Wall Street analysts rating Proteon Therapeutics, 1 give it “Buy”, 0 “Sell” rating, while 7 recommend “Hold”. The lowest target is $1.7000 while the high is $27. The stock’s average target of $8.14 is 340.00% above today’s ($1.85) share price. PRTO was included in 18 notes of analysts from November 11, 2015. JMP Securities downgraded the stock to “Market Perform” rating in Wednesday, December 14 report. Robert W. Baird initiated the stock with “Outperform” rating in Thursday, April 14 report. Raymond James upgraded the shares of PRTO in report on Wednesday, October 26 to “Strong Buy” rating. The rating was downgraded by Stifel Nicolaus on Wednesday, December 14 to “Hold”. Maxim Group initiated Proteon Therapeutics, Inc. (NASDAQ:PRTO) rating on Thursday, November 10. Maxim Group has “Buy” rating and $19 target. The company was downgraded on Friday, March 17 by H.C. Wainwright. The firm has “Market Perform” rating given on Wednesday, December 14 by Cowen & Co. On Wednesday, August 16 the stock rating was maintained by Oppenheimer with “Hold”. The company was initiated on Wednesday, November 11 by Raymond James. The rating was initiated by H.C. Wainwright on Thursday, September 22 with “Buy”.

More notable recent Proteon Therapeutics, Inc. (NASDAQ:PRTO) news were published by: which released: “Proteon Therapeutics’ stock plummets after failed trial of kidney disease …” on December 13, 2016, also with their article: “Proteon Therapeutics Inc.” published on October 20, 2014, published: “Proteon Therapeutics Announces Second Quarter 2017 Financial Results” on August 07, 2017. More interesting news about Proteon Therapeutics, Inc. (NASDAQ:PRTO) were released by: and their article: “Despite PATENCY-1 failure, Proteon Therapeutics vows to press on with vonapanitase” published on December 14, 2016 as well as‘s news article titled: “Have You Ever Heard Of Proteon Therapeutics?” with publication date: July 19, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.